{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:57:45Z","timestamp":1787317065341,"version":"build-2736575974"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10346-x","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:16:39Z","timestamp":1780989399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress"],"prefix":"10.1007","volume":"45","author":[{"given":"Hanqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"1","key":"10346_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","volume":"44","author":"DY Ruan","year":"2024","unstructured":"Ruan, D. Y., Wu, H. X., Meng, Q., & Xu, R. H. (2024). Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer Communications (London, England), 44(1), 3\u201322.","journal-title":"Cancer Communications (London, England)"},{"issue":"2","key":"10346_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li, S., Zhao, X., Fu, K., Zhu, S., Pan, C., Yang, C., et al. (2025). Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B, 15(2), 737\u2013756.","journal-title":"Acta Pharm Sin B."},{"issue":"6","key":"10346_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","volume":"20","author":"MJ Mair","year":"2023","unstructured":"Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., et al. (2023). Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nature Reviews. Clinical Oncology, 20(6), 372\u2013389.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10346_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101126","volume":"77","author":"Y Zou","year":"2024","unstructured":"Zou, Y., Yang, A., Chen, B., Deng, X., Xie, J., Dai, D., et al. (2024). crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resistance Update\u202f: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 77,","journal-title":"Drug Resistance Update : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"1","key":"10346_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., et al. (2019). Brain metastases. Nat Rev Dis Primers., 5(1), 5.","journal-title":"Brain metastases. Nat Rev Dis Primers."},{"issue":"6","key":"10346_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis, M., Gao, Y., Tran, W., Hoey, C., Kiss, A., Komorowski, A. S., et al. (2021). The incidence of brain metastases among patients with metastatic breast cancer: A systematic review and meta-analysis. Neuro-Oncology, 23(6), 894\u2013904.","journal-title":"Neuro-Oncology"},{"issue":"16","key":"10346_CR7","doi-asserted-by":"publisher","first-page":"26368","DOI":"10.18632\/oncotarget.14300","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang, H., Zhang, C., Zhang, J., Kong, L., Zhu, H., & Yu, J. (2017). The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: A SEER based study. Oncotarget, 8(16), 26368\u201379.","journal-title":"Oncotarget"},{"issue":"6","key":"10346_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2022.100866","volume":"46","author":"S Lopes","year":"2022","unstructured":"Lopes, S., Vieira, I., Abreu, M., Pousa, I., Ferreira, A., Sousa, S., et al. (2022). Prognostic factors and survival according to tumor subtype in women with breast cancer brain metastases. Current Problems in Cancer, 46(6)","journal-title":"Current Problems in Cancer"},{"issue":"23","key":"10346_CR9","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., et al. (2010). Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical Cancer Research, 16(23), 5664\u20135678.","journal-title":"Clinical Cancer Research"},{"issue":"26","key":"10346_CR10","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.2174\/138161211797440186","volume":"17","author":"S Agarwal","year":"2011","unstructured":"Agarwal, S., Hartz, A. M., Elmquist, W. F., & Bauer, B. (2011). Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up. Current Pharmaceutical Design, 17(26), 2793\u2013802.","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10346_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/neuonc\/nov164","volume":"18","author":"RK Oberoi","year":"2016","unstructured":"Oberoi, R. K., Parrish, K. E., Sio, T. T., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2016). Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-Oncology, 18(1), 27\u201336.","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10346_CR12","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","volume":"22","author":"MA Vogelbaum","year":"2020","unstructured":"Vogelbaum, M. A., Krivosheya, D., Borghei-Razavi, H., Sanai, N., Weller, M., Wick, W., et al. (2020). Phase 0 and window of opportunity clinical trial design in neuro-oncology: A RANO review. Neuro-Oncology, 22(11), 1568\u20131579.","journal-title":"Neuro-Oncology"},{"key":"10346_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","volume":"135","author":"MA Franzoi","year":"2019","unstructured":"Franzoi, M. A., & Hortobagyi, G. N. (2019). Leptomeningeal carcinomatosis in patients with breast cancer. Critical Reviews in Oncology\/Hematology, 135, 85\u201394.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"5","key":"10346_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou, Y., Ye, F., Kong, Y., Hu, X., Deng, X., Xie, J., et al. (2023). The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh)., 10(5)","journal-title":"Adv Sci (Weinh)."},{"issue":"7","key":"10346_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"WM Pardridge","year":"2016","unstructured":"Pardridge, W. M. (2016). CSF, blood-brain barrier, and brain drug delivery. Expert Opinion on Drug Delivery, 13(7), 963\u2013975.","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10346_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","volume":"165-166","author":"MJ Fowler","year":"2020","unstructured":"Fowler, M. J., Cotter, J. D., Knight, B. E., Sevick-Muraca, E. M., Sandberg, D. I., & Sirianni, R. W. (2020). Intrathecal drug delivery in the era of nanomedicine. Advanced Drug Delivery Reviews, 165\u2013166, 77\u201395.","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"12","key":"10346_CR17","first-page":"742","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. P & T: A Peer-Reviewed Journal for Formulary Management, 42(12), 742\u201355.","journal-title":"P & T: A Peer-Reviewed Journal for Formulary Management"},{"issue":"1","key":"10346_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2024.2375521","volume":"31","author":"N Arshad","year":"2024","unstructured":"Arshad, N., Biswas, N., Gill, J., Kesari, S., & Ashili, S. (2024). Drug delivery in leptomeningeal disease: Navigating barriers and beyond. Drug Delivery, 31(1)","journal-title":"Drug Delivery"},{"issue":"2","key":"10346_CR19","first-page":"698","volume":"131","author":"LP Mangurian","year":"1992","unstructured":"Mangurian, L. P., Walsh, R. J., & Posner, B. I. (1992). Prolactin enhancement of its own uptake at the choroid plexus. Endocrinology, 131(2), 698\u2013702.","journal-title":"Endocrinology"},{"issue":"1-2","key":"10346_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0006-8993(03)03350-X","volume":"988","author":"S Angelow","year":"2003","unstructured":"Angelow, S., Haselbach, M., & Galla, H. J. (2003). Functional characterisation of the active ascorbic acid transport into cerebrospinal fluid using primary cultured choroid plexus cells. Brain Research, 988(1\u20132), 105\u201313.","journal-title":"Brain Research"},{"issue":"6","key":"10346_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3109\/13550280009091950","volume":"6","author":"H Chen","year":"2000","unstructured":"Chen, H., Wood, C., & Petito, C. K. (2000). Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: Potential role of choroid plexus in the pathogenesis of HIV encephalitis. Journal of NeuroVirology, 6(6), 498\u2013506.","journal-title":"Journal of NeuroVirology"},{"issue":"14","key":"10346_CR22","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.1073\/pnas.1433000100","volume":"100","author":"P Kivis\u00e4kk","year":"2003","unstructured":"Kivis\u00e4kk, P., Mahad, D. J., Callahan, M. K., Trebst, C., Tucky, B., Wei, T., et al. (2003). Human cerebrospinal fluid central memory CD4+ T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A., 100(14), 8389\u20138394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10346_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102882","volume":"133","author":"I Michelon","year":"2025","unstructured":"Michelon, I., Castro, C. E. R., Madeira, T., Dacoregio, M. I., Stecca, C., Soares, L. R., et al. (2025). Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis. Cancer Treatment Reviews, 133,","journal-title":"Cancer Treatment Reviews"},{"issue":"6","key":"10346_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., et al. (2026). Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. New England Journal of Medicine, 394(6), 551\u2013562.","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10346_CR25","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","volume":"26","author":"R Bartsch","year":"2025","unstructured":"Bartsch, R., Marhold, M., Garde-Noguera, J., Gion, M., Ruiz-Borrego, M., Greil, R., et al. (2025). Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): A multicentre, single-arm, phase 2 trial. Lancet Oncology, 26(11), 1467\u201378.","journal-title":"Lancet Oncology"},{"issue":"11","key":"10346_CR26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","volume":"26","author":"T Fuereder","year":"2025","unstructured":"Fuereder, T., Garde-Noguera, J., Garc\u00eda-Mosquera, J. J., Ruiz-Borrego, M., Valero, M., Llombart-Cussac, A., et al. (2025). Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): A multicentre, single-arm, phase 2 trial. The lancet Oncology, 26(11), 1454\u20131466.","journal-title":"The lancet Oncology"},{"issue":"8","key":"10346_CR27","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","volume":"31","author":"M Preusser","year":"2025","unstructured":"Preusser, M., Garde-Noguera, J., Garc\u00eda-Mosquera, J. J., Gion, M., Greil, R., Arumi, M., et al. (2025). Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: The phase 2 TUXEDO-3 trial. Nature Medicine, 31(8), 2797\u20132805.","journal-title":"Nature Medicine"},{"issue":"5","key":"10346_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C., & Corva\u00efa, N. (2017). Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 16(5), 315\u2013337.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10346_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie, M., Tchistiakova, L., & Scott, N. (2013). Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs, 5(1), 13\u201321.","journal-title":"MAbs"},{"issue":"5","key":"10346_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang, W., Wang, E. Q., & Balthasar, J. P. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 84(5), 548\u2013558.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10346_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081131","author":"E Ruiz-L\u00f3pez","year":"2021","unstructured":"Ruiz-L\u00f3pez, E., & Schuhmacher, A. J. (2021). Transportation of single-domain antibodies through the blood-brain barrier. Biomolecules. https:\/\/doi.org\/10.3390\/biom11081131","journal-title":"Biomolecules"},{"key":"10346_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152681","author":"VM Medina P\u00e9rez","year":"2024","unstructured":"Medina P\u00e9rez, V. M., Baselga, M., & Schuhmacher, A. J. (2024). Single-domain antibodies as antibody-drug conjugates: From promise to practice-a systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16152681","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10346_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02183-9","volume":"21","author":"C Xu","year":"2023","unstructured":"Xu, C., Zhu, M., Wang, Q., Cui, J., Huang, Y., Huang, X., et al. (2023). TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnology, 21(1)","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"10346_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","volume":"45","author":"XY Zhu","year":"2024","unstructured":"Zhu, X. Y., Li, Q. X., Kong, Y., Huang, K. K., Wang, G., Wang, Y. J., et al. (2024). A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacologica Sinica, 45(3), 609\u201318.","journal-title":"Acta Pharmacologica Sinica"},{"issue":"8","key":"10346_CR35","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","volume":"30","author":"Y Wu","year":"2022","unstructured":"Wu, Y., Li, Q., Kong, Y., Wang, Z., Lei, C., Li, J., et al. (2022). A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Molecular Therapy, 30(8), 2785\u20132799.","journal-title":"Molecular Therapy"},{"issue":"11","key":"10346_CR36","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.7150\/thno.57510","volume":"11","author":"KT Xenaki","year":"2021","unstructured":"Xenaki, K. T., Dorrestijn, B., Muns, J. A., Adamzek, K., Doulkeridou, S., Houthoff, H., et al. (2021). Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics., 11(11), 5525\u20135538.","journal-title":"Theranostics."},{"issue":"12","key":"10346_CR37","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., et al. (2021). Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharmaceutica Sinica B, 11(12), 3889\u2013907.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"10","key":"10346_CR38","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S., Widdison, W., Chari, R., et al. (2010). Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Molecular Cancer Therapeutics, 9(10), 2689\u20132699.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"7","key":"10346_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., et al. (2015). Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology, 33(7), 733\u2013735.","journal-title":"Nature Biotechnology"},{"key":"10346_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","volume":"30","author":"A Pahl","year":"2018","unstructured":"Pahl, A., Lutz, C., & Hechler, T. (2018). Amanitins and their development as a payload for antibody-drug conjugates. Drug Discovery Today. Technologies, 30, 85\u201389.","journal-title":"Drug Discovery Today. Technologies"},{"key":"10346_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6564585","volume":"2021","author":"A Alahmari","year":"2021","unstructured":"Alahmari, A. (2021). Blood-brain barrier overview: Structural and functional correlation. Neural Plasticity, 2021,","journal-title":"Neural Plasticity"},{"key":"10346_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcdb.2014.11.004","volume":"38","author":"RF Haseloff","year":"2015","unstructured":"Haseloff, R. F., Dithmer, S., Winkler, L., Wolburg, H., & Blasig, I. E. (2015). Transmembrane proteins of the tight junctions at the blood-brain barrier: Structural and functional aspects. Seminars in Cell & Developmental Biology, 38, 16\u201325.","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"6","key":"10346_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tins.2008.03.003","volume":"31","author":"NR Saunders","year":"2008","unstructured":"Saunders, N. R., Ek, C. J., Habgood, M. D., & Dziegielewska, K. M. (2008). Barriers in the brain: A renaissance? Trends in Neurosciences, 31(6), 279\u2013286.","journal-title":"Trends in Neurosciences"},{"key":"10346_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314667","author":"AB Chai","year":"2022","unstructured":"Chai, A. B., Callaghan, R., & Gelissen, I. C. (2022). Regulation of P-glycoprotein in the brain. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms232314667","journal-title":"International Journal of Molecular Sciences"},{"key":"10346_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014134","author":"Y Zou","year":"2026","unstructured":"Zou, Y., Wu, J., Yuan, Z., He, X., & Tang, H. (2026). Targeting the neuro-immune crosstalk in breast cancer brain metastases. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2025-014134","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"10346_CR46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., et al. (2010). Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics, 87(5), 586\u2013592.","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10346_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s004010000180","volume":"100","author":"S Liebner","year":"2000","unstructured":"Liebner, S., Fischmann, A., Rascher, G., Duffner, F., Grote, E. H., Kalbacher, H., et al. (2000). Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathologica, 100(3), 323\u2013331.","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"10346_CR48","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neuroscience.2004.05.044","volume":"129","author":"MC Papadopoulos","year":"2004","unstructured":"Papadopoulos, M. C., Saadoun, S., Binder, D. K., Manley, G. T., Krishna, S., & Verkman, A. S. (2004). Molecular mechanisms of brain tumor edema. Neuroscience, 129(4), 1011\u201320.","journal-title":"Neuroscience"},{"issue":"11","key":"10346_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","volume":"18","author":"PS Steeg","year":"2021","unstructured":"Steeg, P. S. (2021). The blood-tumour barrier in cancer biology and therapy. Nature Reviews Clinical Oncology, 18(11), 696\u2013714.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"21","key":"10346_CR50","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-15-1836","volume":"22","author":"LT Lyle","year":"2016","unstructured":"Lyle, L. T., Lockman, P. R., Adkins, C. E., Mohammad, A. S., Sechrest, E., Hua, E., et al. (2016). Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clinical Cancer Research, 22(21), 5287\u20135299.","journal-title":"Clinical Cancer Research"},{"key":"10346_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag002","author":"I Khan","year":"2026","unstructured":"Khan, I., Kumar, D., Zhang, W., Difilippantonio, S., Robinson, C., Wei, D., et al. (2026). Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier and distribution to tumor cells in HER2+ brain metastasis model systems. Neuro-Oncology. https:\/\/doi.org\/10.1093\/neuonc\/noag002","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10346_CR52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","volume":"29","author":"S Kabraji","year":"2023","unstructured":"Kabraji, S., Ni, J., Sammons, S., Li, T., Van Swearingen, A. E. D., Wang, Y., et al. (2023). Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research, 29(1), 174\u2013182.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10346_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2533488","volume":"14","author":"O Kepp","year":"2025","unstructured":"Kepp, O., & Kroemer, G. (2025). Immunogenic cell death and bystander killing: Expanding the therapeutic potential of modern antibody-drug conjugates. Oncoimmunology, 14(1)","journal-title":"Oncoimmunology"},{"issue":"8_Supplement_1","key":"10346_CR54","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/1538-7445.AM2025-2160","volume":"85","author":"N Schulte","year":"2025","unstructured":"Schulte, N., Ikuta, M., Mertes, A., Kanchev, I., Deguchi, T., & Polier, G. (2025). Abstract 2160: Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and -migration in viable human breast cancer slices. Cancer Research, 85(8_Supplement_1), 2160.","journal-title":"Cancer Research"},{"issue":"5","key":"10346_CR55","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter, F. W., Barker, H. R., Lipert, B., Roth\u00e9, F., Gebhart, G., Piccart-Gebhart, M. J., et al. (2020). Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer, 122(5), 603\u2013612.","journal-title":"British Journal of Cancer"},{"issue":"19","key":"10346_CR56","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England Journal of Medicine, 367(19), 1783\u20131791.","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10346_CR57","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop, I. E., Kim, S. B., Martin, A. G., LoRusso, P. M., Ferrero, J. M., Badovinac-Crnjevic, T., et al. (2017). Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. The lancet Oncology, 18(6), 743\u2013754.","journal-title":"The lancet Oncology"},{"issue":"1","key":"10346_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., et al. (2015). Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Annals of Oncology, 26(1), 113\u2013119.","journal-title":"Annals of Oncology"},{"issue":"10","key":"10346_CR59","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro, F., Delaloge, S., Barrios, C. H., Wuerstlein, R., Anton, A., Brain, E., et al. (2020). Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Annals of Oncology, 31(10), 1350\u20131358.","journal-title":"Annals of Oncology"},{"key":"10346_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.breast.2018.07.004","volume":"41","author":"A Fabi","year":"2018","unstructured":"Fabi, A., Alesini, D., Valle, E., Moscetti, L., Caputo, R., Caruso, M., et al. (2018). T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. Breast, 41, 137\u2013143.","journal-title":"Breast"},{"issue":"11","key":"10346_CR61","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","volume":"35","author":"RA Freedman","year":"2024","unstructured":"Freedman, R. A., Heiling, H. M., Li, T., Trapani, D., Tayob, N., Smith, K. L., et al. (2024). Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational breast cancer research consortium trial 022. Annals of Oncology, 35(11), 993\u20131002.","journal-title":"Annals of Oncology"},{"issue":"3","key":"10346_CR62","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","volume":"35","author":"C Saura","year":"2024","unstructured":"Saura, C., Modi, S., Krop, I., Park, Y. H., Kim, S. B., Tamura, K., et al. (2024). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology, 35(3), 302\u20137.","journal-title":"Annals of Oncology"},{"issue":"12","key":"10346_CR63","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","volume":"12","author":"G Jerusalem","year":"2022","unstructured":"Jerusalem, G., Park, Y. H., Yamashita, T., Hurvitz, S. A., Modi, S., Andre, F., et al. (2022). Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discovery, 12(12), 2754\u20132762.","journal-title":"Cancer Discovery"},{"issue":"5","key":"10346_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102924","volume":"9","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz, S. A., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., et al. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open., 9(5)","journal-title":"ESMO Open."},{"issue":"12","key":"10346_CR65","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","volume":"35","author":"F Andr\u00e9","year":"2024","unstructured":"Andr\u00e9, F., Cort\u00e9s, J., Curigliano, G., Modi, S., Li, W., Park, Y. H., et al. (2024). A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Annals of Oncology, 35(12), 1169\u201380.","journal-title":"Annals of Oncology"},{"issue":"12","key":"10346_CR66","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N., Ciruelos, E., Jerusalem, G., M\u00fcller, V., Niikura, N., Viale, G., et al. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b\/4 trial. Nature Medicine, 30(12), 3717\u20133727.","journal-title":"Nature Medicine"},{"issue":"9","key":"10346_CR67","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider-Schur, S., et al. (2022). Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nature Medicine, 28(9), 1840\u20131847.","journal-title":"Nature Medicine"},{"issue":"1","key":"10346_CR68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda, J. M., Vaz Batista, M., Cortez, P., Ruiz-Borrego, M., Cejalvo, J. M., de la Haba-Rodriguez, J., et al. (2023). Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro-Oncology, 25(1), 157\u2013166.","journal-title":"Neuro-Oncology"},{"key":"10346_CR69","doi-asserted-by":"crossref","unstructured":"Anders C, Loi S, Hamilton E, Jhaveri K, Schmid P, G\u00f6kmen E, et al. NVTG-07 safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXD) in patients with HER2+ metastatic breast cancer (mbc) and active brain metastases (BMS) in DESTINY-Breast07 (DB-07). Neuro-Oncology Advances\u00a02024;6(Supplement_1):i25-i.","DOI":"10.1093\/noajnl\/vdae090.081"},{"issue":"8","key":"10346_CR70","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine, 372(8), 724\u2013734.","journal-title":"New England Journal of Medicine"},{"key":"10346_CR71","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer.\u00a0 N Engl J Med.\u00a0\u00a02025.","DOI":"10.1056\/NEJMoa2508668"},{"issue":"1","key":"10346_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., et al. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387(1), 9\u201320.","journal-title":"New England Journal of Medicine"},{"key":"10346_CR73","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1016\/j.annonc.2023.09.553","volume":"34","author":"S Modi","year":"2023","unstructured":"Modi, S., Jacot, W., Iwata, H., Park, Y. H., Losada, M. J. V., Li, W., et al. (2023). 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. Annals of Oncology., 34, S334\u2013S335.","journal-title":"Annals of Oncology."},{"issue":"22","key":"10346_CR74","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O\u2019Shaughnessy, J. A., et al. (2024). Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. The New England Journal of Medicine, 391(22), 2110\u201322.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10346_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41523-021-00341-6","volume":"7","author":"M Aslan","year":"2021","unstructured":"Aslan, M., Hsu, E. C., Garcia-Marques, F. J., Bermudez, A., Liu, S., Shen, M., et al. (2021). Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer., 7(1), 141.","journal-title":"NPJ Breast Cancer."},{"issue":"26","key":"10346_CR76","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015). Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget, 6(26), 22496\u201322512.","journal-title":"Oncotarget"},{"issue":"1","key":"10346_CR77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz, S. A., Bardia, A., Punie, K., Kalinsky, K., Carey, L. A., Rugo, H. S., et al. (2024). Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer., 10(1), 33.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"10346_CR78","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda, H. U., Kelly, W. J., Kaklamani, V. G., Lathrop, K. I., Canola, M. M., Ghamasaee, P., et al. (2024). Sacituzumab govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: A phase 0 window-of-opportunity trial. Nature Communications, 15(1), 6707.","journal-title":"Nature Communications"},{"issue":"12","key":"10346_CR79","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., et al. (2021). Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Molecular Cancer Therapeutics, 20(12), 2329\u20132340.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10346_CR80","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia, A., Jhaveri, K., Im, S. A., Pernas, S., De Laurentiis, M., Wang, S., et al. (2025). Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. Journal of Clinical Oncology, 43(3), 285\u2013296.","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10346_CR81","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent, R. A., Cescon, D. W., Bachelot, T., Jung, K. H., Shao, Z. M., Saji, S., et al. (2023). TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncology, 19(35), 2349\u20132359.","journal-title":"Future Oncology"},{"key":"10346_CR82","doi-asserted-by":"publisher","first-page":"S1566","DOI":"10.1016\/j.annonc.2025.09.031","volume":"36","author":"RA Dent","year":"2025","unstructured":"Dent, R. A., Shao, Z., Schmid, P., Cort\u00e9s, J. C., Cescon, D. W., Saji, S., et al. (2025). LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Annals of Oncology., 36, S1566\u2013S1567.","journal-title":"Annals of Oncology."},{"key":"10346_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01008-y","author":"JT Garrett","year":"2025","unstructured":"Garrett, J. T., Tendler, S., Feroz, W., Kilroy, M. K., & Yu, H. (2025). Emerging importance of HER3 in tumorigenesis and cancer therapy. Nature Reviews Clinical Oncology. https:\/\/doi.org\/10.1038\/s41571-025-01008-y","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"16","key":"10346_CR84","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-23-0020","volume":"29","author":"E Tomasich","year":"2023","unstructured":"Tomasich, E., Steindl, A., Paiato, C., Hatziioannou, T., Kleinberger, M., Berchtold, L., et al. (2023). Frequent overexpression of HER3 in brain metastases from breast and lung cancer. Clinical Cancer Research, 29(16), 3225\u20133236.","journal-title":"Clinical Cancer Research"},{"issue":"23","key":"10346_CR85","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","volume":"25","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto, Y., Koyama, K., Kamai, Y., Hirotani, K., Ogitani, Y., Zembutsu, A., et al. (2019). A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clinical Cancer Research, 25(23), 7151\u20137161.","journal-title":"Clinical Cancer Research"},{"issue":"36","key":"10346_CR86","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop, I. E., Masuda, N., Mukohara, T., Takahashi, S., Nakayama, T., Inoue, K., et al. (2023). Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I\/II trial. J Clin Oncol, 41(36), 5550\u201360.","journal-title":"J Clin Oncol"},{"issue":"35","key":"10346_CR87","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., et al. (2023). HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. Journal of Clinical Oncology, 41(35), 5363\u20135375.","journal-title":"Journal of Clinical Oncology"},{"key":"10346_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122910","volume":"352","author":"MJ Khosravanian","year":"2024","unstructured":"Khosravanian, M. J., Mirzaei, Y., Mer, A. H., Keyhani-Khankahdani, M., Abdinia, F. S., Misamogooe, F., et al. (2024). Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence. Life Sci, 352,","journal-title":"Life Sci"},{"key":"10346_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203437","author":"P Gonnet","year":"2024","unstructured":"Gonnet, P., Marinari, E., Achard, V., Schaffar, R., Neyroud-Caspar, I., May, A., et al. (2024). Brain metastases from genito-urinary cancers in the Canton of Geneva (Switzerland): Study of incidence, management and outcomes. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16203437","journal-title":"Cancers (Basel)"},{"key":"10346_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030375","author":"C Vulsteke","year":"2023","unstructured":"Vulsteke, C., De Cocker, L., G\u00f3mez de Lia\u00f1o, A., Montesdeoca, C., De Meulenaere, A., Croes, L., et al. (2023). First evidence of activity of enfortumab vedotin on brain metastases in urothelial cancer patients. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph16030375","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"1","key":"10346_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.08.001","volume":"6","author":"M Vaz Batista","year":"2025","unstructured":"Vaz Batista, M., P\u00e9rez-Garc\u00eda, J. M., Garrig\u00f3s, L., Garc\u00eda-S\u00e1enz, J., Cortez, P., Racca, F., et al. (2025). The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med, 6(1)","journal-title":"Med"},{"issue":"14","key":"10346_CR92","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu, Y. L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., et al. (2024). Alectinib in resected ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 390(14), 1265\u20131276.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10346_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","volume":"15","author":"TM Bauer","year":"2020","unstructured":"Bauer, T. M., Shaw, A. T., Johnson, M. L., Navarro, A., Gainor, J. F., Thurm, H., et al. (2020). Brain penetration of lorlatinib: Cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Targeted Oncology, 15(1), 55\u201365.","journal-title":"Targeted Oncology"},{"issue":"10","key":"10346_CR94","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","volume":"20","author":"K Pan","year":"2023","unstructured":"Pan, K., Concannon, K., Li, J., Zhang, J., Heymach, J. V., & Le, X. (2023). Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer. Nature Reviews Clinical Oncology, 20(10), 716\u2013732.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"3","key":"10346_CR95","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar, P. U., Avram, M. J., Lassman, A. B., Lin, N. U., Lee, E., Grimm, S. A., et al. (2023). A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncology, 25(3), 557\u2013565.","journal-title":"Neuro-Oncology"},{"issue":"33","key":"10346_CR96","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.22.01148","volume":"40","author":"JT Yang","year":"2022","unstructured":"Yang, J. T., Wijetunga, N. A., Pentsova, E., Wolden, S., Young, R. J., Correa, D., et al. (2022). Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. Journal of Clinical Oncology, 40(33), 3858\u20133867.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10346_CR97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11060-024-04788-y","volume":"170","author":"D Rogawski","year":"2024","unstructured":"Rogawski, D., Cao, T., Ma, Q., Roy-O\u2019Reilly, M., Yao, L., Xu, N., et al. (2024). Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression. Journal of Neuro-Oncology, 170(1), 209\u2013217.","journal-title":"Journal of Neuro-Oncology"},{"key":"10346_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112908","author":"S Warrior","year":"2023","unstructured":"Warrior, S., Cohen-Nowak, A., & Kumthekar, P. (2023). Modern management and diagnostics in HER2+ breast cancer with CNS metastasis. Cancers (Basel, Switzerland). https:\/\/doi.org\/10.3390\/cancers15112908","journal-title":"Cancers (Basel, Switzerland)"},{"key":"10346_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114949","volume":"199","author":"R Ajeeb","year":"2023","unstructured":"Ajeeb, R., & Clegg, J. R. (2023). Intrathecal delivery of macromolecules: Clinical status and emerging technologies. Advanced Drug Delivery Reviews, 199,","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"1","key":"10346_CR100","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"F Zagouri","year":"2013","unstructured":"Zagouri, F., Sergentanis, T. N., Bartsch, R., Berghoff, A. S., Chrysikos, D., de Azambuja, E., et al. (2013). Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Research and Treatment, 139(1), 13\u201322.","journal-title":"Breast Cancer Research and Treatment"},{"key":"10346_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210873","volume":"13","author":"A de Bernardi","year":"2023","unstructured":"de Bernardi, A., Bachelot, T., & Larrouqu\u00e8re, L. (2023). Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: A case report and review of the literature. Frontiers in Oncology, 13,","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10346_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac130","volume":"4","author":"KA Porath","year":"2022","unstructured":"Porath, K. A., Regan, M. S., Griffith, J. I., Jain, S., Stopka, S. A., Burgenske, D. M., et al. (2022). Convection enhanced delivery of EGFR targeting antibody-drug conjugates serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neuro-Oncology Advances, 4(1)","journal-title":"Neuro-Oncology Advances"},{"issue":"37","key":"10346_CR103","first-page":"E8717","volume":"115","author":"CD Arvanitis","year":"2018","unstructured":"Arvanitis, C. D., Askoxylakis, V., Guo, Y., Datta, M., Kloepper, J., Ferraro, G. B., et al. (2018). Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proceedings of the National Academy of Sciences of the United States of America, 115(37), E8717-e26.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10346_CR104","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar, P., Tang, S. C., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C., et al. (2020). ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clinical Cancer Research, 26(12), 2789\u20132799.","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10346_CR105","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1039\/D1RA08131D","volume":"12","author":"Y Anami","year":"2022","unstructured":"Anami, Y., Xiong, W., Yamaguchi, A., Yamazaki, C. M., Zhang, N., An, Z., et al. (2022). Homogeneous antibody-angiopep 2 conjugates for effective brain targeting. RSC Advances, 12(6), 3359\u20133364.","journal-title":"RSC Advances"},{"issue":"1","key":"10346_CR106","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/1535-7163.MCT-14-0399","volume":"14","author":"A Regina","year":"2015","unstructured":"Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J. C., Iddir, M., et al. (2015). ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Molecular Cancer Therapeutics, 14(1), 129\u2013140.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10","key":"10346_CR107","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/neuonc\/noab041","volume":"23","author":"W Wang","year":"2021","unstructured":"Wang, W., He, H., Mar\u00edn-Ramos, N. I., Zeng, S., Swenson, S. D., Cho, H. Y., et al. (2021). Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro-Oncology, 23(10), 1656\u201367.","journal-title":"Neuro-Oncology"},{"key":"10346_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106934","volume":"196","author":"M Sevieri","year":"2023","unstructured":"Sevieri, M., Mazzucchelli, S., Barbieri, L., Garbujo, S., Carelli, S., Bonizzi, A., et al. (2023). Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis. Pharmacological Research, 196,","journal-title":"Pharmacological Research"},{"issue":"11","key":"10346_CR109","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., et al. (2021). EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology, 32(11), 1332\u20131347.","journal-title":"Annals of Oncology"},{"issue":"5","key":"10346_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101624","volume":"8","author":"E Le Rhun","year":"2023","unstructured":"Le Rhun, E., Weller, M., van den Bent, M., Brandsma, D., Furtner, J., Rud\u00e0, R., et al. (2023). Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open, 8(5)","journal-title":"ESMO Open"},{"issue":"2","key":"10346_CR111","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., et al. (2017). Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 19(2), 162\u201374.","journal-title":"Neuro-Oncology"},{"key":"10346_CR112","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","volume":"359","author":"A Beishenaliev","year":"2023","unstructured":"Beishenaliev, A., Loke, Y. L., Goh, S. J., Geo, H. N., Mugila, M., Misran, M., et al. (2023). Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. Journal of Controlled Release, 359, 268\u2013286.","journal-title":"Journal of Controlled Release"},{"issue":"7","key":"10346_CR113","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann, R. E., & Brinkmann, U. (2015). Bispecific antibodies. Drug Discovery Today, 20(7), 838\u201347.","journal-title":"Drug Discovery Today"},{"issue":"1","key":"10346_CR114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., et al. (2016). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell, 29(1), 117\u201329.","journal-title":"Cancer Cell"},{"issue":"1","key":"10346_CR115","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","volume":"96","author":"X Ji","year":"2026","unstructured":"Ji, X., Yang, Y., Ma, C., Huang, W., Guo, S., Wang, L., et al. (2026). Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemotherapy and Pharmacology, 96(1), 15.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"7","key":"10346_CR116","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y., Huang, Y., Zhao, Y., Zhao, S., Xue, J., Yang, Y., et al. (2024). BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study. Lancet Oncology, 25(7), 901\u2013911.","journal-title":"Lancet Oncology"},{"issue":"2","key":"10346_CR117","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41401-025-01634-3","volume":"47","author":"Y Wang","year":"2026","unstructured":"Wang, Y., Liu, L., Yang, Q. Y., & Yu, K. (2026). Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy. Acta Pharmacologica Sinica, 47(2), 467\u2013480.","journal-title":"Acta Pharmacologica Sinica"},{"issue":"6","key":"10346_CR118","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., et al. (2020). Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Research, 80(6), 1268\u201378.","journal-title":"Cancer Research"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10346-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:03:49Z","timestamp":1780995829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10346-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":118,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10346"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10346-x","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}